Loading clinical trials...
Loading clinical trials...
A Phase 1, Randomized, Double Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy Participants Followed by a Phase 2a Open Label Study in Participants With PNH and Residual Anemia to Evaluate the Safety, Tolerability, PK and PD of ADX-038
Conditions
Interventions
ADX-038
Placebo
Locations
4
Australia
Nucleus Network Brisbane
Brisbane, Queensland, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Royal Melbourne Hospital
Parkville, Victoria, Australia
Richmond Pharmacology Ltd
London, United Kingdom
Start Date
August 7, 2023
Primary Completion Date
March 31, 2028
Completion Date
July 31, 2028
Last Updated
April 22, 2026
NCT06312644
NCT03520647
NCT07152288
NCT07108023
NCT03056040
NCT05116774
Lead Sponsor
ADARx Pharmaceuticals, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions